Teewinot Life Sciences Corporation, headquartered in Tampa, Florida,USA, is an innovative global biotechnology company that has created proprietary, disruptive biosynthetic manufacturing to dominate rapidly evolving cannabinoid consumer and pharmaceutical markets. We provide novel solutions, including the production of molecules that are found in low abundance from natural sources, as well as cannabinoid-based A prodrug is a compound that, after administration, is metabolized within the body into a pharmacologically active drug product. prodrugs and A cannabinoid analog is a compound that has a similar structure to the naturally-occurring phytocannabinoid but its chemical structure has been modified to improve its activity, bioavailability, or some other characteristic. analogs in commercially-scalable quantities. To accomplish these tasks Teewinot, and its wholly owned subsidiaries, Teewinot Technologies Ltd and Teewinot Laboratories, Inc. (collectively called Teewinot), developed proprietary and cost-effective methods for biosynthesis of cannabinoids that have the identical chemical structure to naturally occurring phytocannabinoids. Teewinot combines its biosynthetic processes with sophisticated chemical synthesis to produce proprietary cannabinoid analogs and prodrugs. An aggressive intellectual property protection program has been implemented with patent applications filed in key countries around the world. Our company combines cutting edge scientific research on cannabinoids with an aggressive intellectual property portfolio to build significant value and create new and improved patient therapies.
Teewinot maintains strict compliance with all applicable government regulations in every jurisdiction in which we operate. As such, our wholly owned subsidiaries are in jurisdictions favorable to research, development, and operational functions. Teewinot Laboratories, Inc. (TLabs), headquartered near Winnipeg, Manitoba, Canada, holds a controlled substances licence from Health Canada to work with cannabinoids. The recently expanded main laboratory facility houses significant research capacity in the fields of microbiology, molecular biology, chemistry, genetics, and formulation technologies. With a second laboratory in Burnaby, BC, Canada, Tlabs will further enhance in-house capabilities in synthetic biology, biosynthesis, biocatalysis, microbiology and organic chemistry. Teewinot Technologies Ltd (TTech), is headquartered in Dublin, Ireland. TTech owns the corporation’s intellectual property and therefore is engaged in licensing activities. Located in the European Union, TTech provides beneficial access to significant global markets.
We are committed to unlocking the therapeutic potential of cannabinoids through innovative research and advanced formulation technology. Teewinot enjoys commercial first-mover advantage in the area of cannabinoid biosynthesis with patents containing granted claims covering biosynthetic processes and equipment for the manufacture of cannabinoids, as well as water-soluble cannabinoid formulation technology. By understanding the complexities of cannabinoid production using biosynthetic methods, we are able to apply fundamental process technology to cost-effectively produce cannabinoid-based pharmaceuticals that are authentic, meaning the biosynthetic cannabinoids have the same chemical structure as naturally occurring phytocannabinoids found in the Cannabis plant. Using its innovative biosynthetic processes, Teewinot is able to cost-effectively manufacture commercially significant quantities of authentic cannabinoids that are only produced in the Cannabis plant in small quantities.
Furthermore, these biosynthetic processes can be adapted to cost-effectively manufacture novel and proprietary cannabinoid analogs and cannabinoid prodrugs potentially suitable for a variety of therapeutic applications.
Our in-house research and development team has specialized training and expertise in the fields of:
- Synthetic Biology
- Formulation Science
- Product Development
Our R&D capabilities are further strengthened through strategic relationships with accomplished and respected Contract Research Organizations (CRO) and Contract Manufacturing Organizations (CMO).
Teewinot has a disciplined approach to research and development with targeted applications. Our innovative technologies allow us to quickly turn around customized product solutions and to address formulation challenges. In particular, we are actively engaged in developing new therapeutic compounds based on authentic cannabinoids. By authentic cannabinoids we mean biosynthetically produced cannabinoids having the identical chemical structure to naturally-occurring phytocannabinoids. These new therapeutic compounds include prodrugs and analogs.
A cannabinoid analog is a compound that has a similar structure to the naturally-occurring phytocannabinoid but its chemical structure has been modified to improve its activity, bioavailability, or some other characteristic.
A prodrug is a compound that, after administration, is metabolized within the body into a pharmacologically active drug product.
Teewinot is available to help commercial partners develop or manufacture new cannabinoid-based pharmaceuticals, prodrugs or analogs.
It is true that there is strength in numbers and Teewinot believes in collaborating with research institutions, consumer product companies, manufacturers, and our local communities to generate new and effective therapies.